で公開中です! 詳しく見る
AMPHのアイコン

Amphastar Pharmaceuticals

25.87 USD
-0.55
2.08%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
25.80
-0.07
0.27%
1日
-2.08%
5日間
-2.82%
1か月
8.02%
3か月
30.26%
6か月
18.62%
年初来
-2.23%
1年
11.41%
5年間
35.94%
10年間
43.4%
 

概要: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

従業員数: 1,976

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 33.3%
ニュートラル 41.7%
ネガティブ 25%
ポジティブ
Zacks Investment Research
11 日前
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
ニュートラル
PRNewsWire
先月
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
ポジティブ
Zacks Investment Research
先月
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
ネガティブ
Zacks Investment Research
2 か月前
New Strong Sell Stocks for August 14th
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
New Strong Sell Stocks for August 14th
ニュートラル
Seeking Alpha
2 か月前
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
ポジティブ
Zacks Investment Research
2 か月前
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
ポジティブ
Zacks Investment Research
2 か月前
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share a year ago.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
ネガティブ
MarketBeat
2 か月前
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
ニュートラル
PRNewsWire
2 か月前
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
ネガティブ
Zacks Investment Research
2 か月前
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
価格チャートは Lightweight Charts™ を使用して実装されています